Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure. (Q38351585)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

review article

1 reference

title

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

0 references

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Mirjam Zeisel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Julie Lucifora

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Massimo Levrero

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Percy A. Knolle

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

François-Loic Cosset

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jia-Horng Kao

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Fabrice Carrat

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Fabien Zoulim

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Françoise Barré-Sinoussi

20

object named as

Françoise Barré-Sinoussi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

19

Raymond F Schinazi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

4

Camille Sureau

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

11

Marie-Louise Michel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

15

Christian Trépo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jean-François Delfraissy

21

object named as

Jean-François Delfraissy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Monsef Benkirane

9

object named as

Monsef Benkirane

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

William S Mason

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jürgen Beck

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Michael Kann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Hélène Strick-Marchand

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Karine Lacombe

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Brigitte Autran

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

10 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

1314-1326

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25670809%20AND%20SRC:MED&resulttype=core&format=json

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Towards an HIV cure: a global scientific strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

The oncogenic role of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Innate immunity of the newborn: basic mechanisms and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Fighting against viral hepatitis: lessons from Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Global control of hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Risk stratification for hepatitis B virus related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Are novel combination therapies needed for chronic hepatitis B?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Reactivation of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

New insight in the pathobiology of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

The tree shrews: adjuncts and alternatives to primates as models for biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Infection of a human hepatoma cell line by hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Genomic analysis of the host response to hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

The woodchuck: a model for therapeutic vaccination against hepadnaviral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

21 January 2018

Mice with human livers

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Small animal model systems for studying hepatitis B virus replication and pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Transfer of HBV Genomes Using Low Doses of Adenovirus Vectors Leads to Persistent Infection in Immune Competent Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus genomes that cannot synthesize pre-S2 proteins occur frequently and as dominant virus populations in chronic carriers in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Role of N Glycosylation of Hepatitis B Virus Envelope Proteins in Morphogenesis and Infectivity of Hepatitis Delta Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

A function essential to viral entry underlies the hepatitis B virus "a" determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

The first transmembrane domain of the hepatitis B virus large envelope protein is crucial for infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus infection is dependent on cholesterol in the viral envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Strategies to inhibit entry of HBV and HDV into hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Nucleoporin 153 arrests the nuclear import of hepatitis B virus capsids in the nuclear basket

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Structural organization of the hepatitis B virus minichromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Involvement of host cellular multivesicular body functions in hepatitis B virus budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Liver antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Living in the liver: hepatic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Immunology of hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

The host-pathogen interaction during HBV infection: immunological controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Early kinetics of innate and adaptive immune responses during hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Control of hepatitis B virus replication by innate response of HepaRG cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Innate antiviral immune responses to hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Kupffer cell-derived IL-10 plays a key role in maintaining humoral immune tolerance in hepatitis B virus-persistent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

HIV accessory proteins versus host restriction factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Elite controllers as a model of functional cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Blimp-1 overexpression is associated with low HIV-1 reservoir and transcription levels in central memory CD4+ T cells from elite controllers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Emerging antivirals for the treatment of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Emerging pipeline drugs for hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus resistance to nucleos(t)ide analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Management of treatment failure in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Characterization of metabolites of GLS4 in humans using ultrahigh-performance liquid chromatography/quadrupole time-of-flight mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Targeted DNA mutagenesis for the cure of chronic viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Host factor-targeted hepatitis B virus therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

An anti-viral peptide derived from the preS1 surface protein of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Curing chronic hepatitis C--the arc of a medical triumph

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943

Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-308943